# The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

> **NCT01159665** · PHASE2 · COMPLETED · sponsor: **ThromboGenics** · enrollment: 38 (actual)

## Conditions studied

- Vitrectomy

## Interventions

- **DRUG:** ocriplasmin
- **DRUG:** ocriplasmin
- **DRUG:** ocriplasmin
- **DRUG:** ocriplasmin
- **DRUG:** ocriplasmin

## Key facts

- **NCT ID:** NCT01159665
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-11
- **Final completion:** 2011-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159665, "The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*